Physician profile
Muhammad Khan
NPI 1417922261
$1,419.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $55.18 · 2021: $13.31 · 2022: $212 · 2023: $288 · 2024: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434 · Travel and Lodging: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.80 |
| Travel and Lodging | $387.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $387.09 | 2024 | Zoom 88-T Large Distal Platform |
| Qapel Medical INC | $288.11 | 2023 | |
| Abbvie INC. | $166.06 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $159.34 | 2019-2020 | |
| Alkermes, INC. | $89.24 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.99 | 2022 | |
| Allergan, INC. | $46.41 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.69 | 2019 | |
| Eisai INC. | $33.54 | 2020 | |
| Ironshore Pharmaceuticals INC. | $21.70 | 2019 | |
| Tris Pharma INC | $21.37 | 2019 | |
| Shire North American Group INC | $20.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.64 | 2022 | |
| Emd Serono, INC. | $14.26 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.31 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.